The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Relapse after HSCT 2021 | Challenges of CAR-T therapy for CLL
Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, talks on the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients with chronic lymphocytic leukemia (CLL). Prof. Dreger explains that patients with specific genetic aberrations indicative of a poor prognosis, such as tp53 alterations and complex karyotypes, are good candidates for cellular therapy. Nevertheless, due to the immunosuppressive properties of CLL cells, CAR-T therapy is not as effective as in other B-lymphoid malignancies. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
